IL2 and hereditary clear cell renal cell carcinoma: IL-2 and IFNα were the first immunomodulators used to treat melanoma and renal cell carcinoma (Waldmann, 2018), and molecules that target the IL-2 and IFNAR pathways are FDA-approved for some cancer types.